MULTI-CENTER STUDY OF HYDROXYUREA IN SICKLE CELL ANEMIA (MSH) PATIENTS FOLLOW

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项关于羟基脲治疗镰状细胞性贫血的多中心研究有三个具体目标。第一个目的是确定新出现的严重医疗状况和特定器官或系统的渐进性损伤或衰竭。第二个目的是评估所有死亡原因，并对入组MSH后患者后代发生的出生缺陷进行分类。第三个目标是评估患者的生活质量。 MSH旨在检测羟基脲是否降低镰状细胞性贫血患者血管闭塞发作的发生率，而不是检测治疗组之间死亡率的差异。患者必须满足一个入选标准，即MSH入组史。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There are three specific aims to this multi-center study of hydroxyurea in sickle cell anemia. The first aim is to identify newly arising serious medical conditions and progressive impairment or failure of specific organs or systems. The second aim is to assess all cause of mortality and classify birth defects occuring in the offspring of patients since enrollment in the MSH. The third aim is to assess the quality of life for the patients. The MSH was designed to test whether hydroxyurea reduced the incidence of vaso-occlusive episodes in sickle-cell anemia and not to detect differences in mortality between treatment groups. Patients must meet only one inclusion criteria, a history of enrollment in the MSH.